Article citationsMore>>
Shah, C., Miller, T.W., Wyatt, S.K., McKinley, E.T., Olivares, M.G., Sanchez, V., Nolting, D.D., Buck, J.R., Zhao, P., Ansari, M.S., Baldwin, R.M., Gore, J.C., Schiff, R., Arteaga, C.L. and Manning, H.C. (2009) Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer. Clinical Cancer Research, 15, 4712-4721.
http://dx.doi.org/10.1158/1078-0432.CCR-08-2635
has been cited by the following article:
-
TITLE:
Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [18F]Fluorothymidine-PET
AUTHORS:
Nicolas Graf, Zhoulei Li, Ken Herrmann, Michaela Aichler, Jolanta Slawska, Axel Walch, Christian Peschel, Markus Schwaiger, Andreas K. Buck, Tobias Dechow, Ulrich Keller
KEYWORDS:
CD40 Antibody, FLT-PET, Lymphoma, Therapy Monitoring
JOURNAL NAME:
Advances in Molecular Imaging,
Vol.5 No.2,
April
9,
2015
ABSTRACT: Background: Inhibition of the lymphoma surface antigen CD40 by the
antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various
lymphoma subtypes. In this preclinical in
vivo study we examined the suitability of positron emission tomography
(PET) using the thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine
(FLT) for early response assessment upon HCD122 treatment in diffuse large B
cell lymphoma (DLBCL). Methods: Immunodeficient mice bearing human DLBCL
xenografts (SU-DHL-4) received weekly intraperitoneal injections of HCD122.
Tumor growth was followed up until Day 14. Molecular imaging with FLT-PET was
performed before (Day 0) and after start of therapy (Day 2 and Day 7). On Day 14
lymphoma xenografts were explanted for immunohistochemical analysis to correlate
PET findings with CD40 surface expression on tumor tissue. Results: Treatment
with HCD122 significantly delayed tumor growth resulting in a tumor growth
inhibition of 45% on Day 14. Significant reduction of tumor-to-background ratio
(TBR) of FLT-PET was seen in treated animals on Day 7 and preceded change of
tumor volume, thus predicting therapy response to HCD122. Immunohistochemical
analysis of xenografts revealed significantly higher CD40 expression on treated
than on untreated tissue. Moreover, we found a significant correlation between
CD40 expression and FLT-PET response for xenograft tumor treated with HCD122. Conclusions:
Treatment of DLBCL with the antagonistic CD40 antibody HCD122 can be monitored
with FLT-PET as early as seven days after commencement of therapy and seems to
increase CD40 expression on tumor tissue.
Related Articles:
-
Kenneth M. Wong, Theodore Scott Nowicki, Carmelo Puccio, Tauseef Ahmed, Raj Tiwari, Jan Geliebter, Augustine Moscatello
-
Joseph R. Scalea, Branko Bojovic, Robin Legros, Julia Choi, Andrea Hebert, Nader Hanna
-
Mari Ikeda, Hisako Kanai, Misato Osaka, Nao Tamai, Yukie Takemura, Hiromi Sanada
-
Ning Li, Wen Tan, Jing Li, Ping Li, Simon Lee, Yitao Wang, Yuewen Gong
-
Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia